X0306 4 2015-04-07 0 0001623613 Mylan N.V. MYL 0000001800 ABBOTT LABORATORIES 100 ABBOTT PARK ROAD ABBOTT PARK IL 60064-6092 0 0 1 0 0001635611 Abbott Established Products Holdings Gibraltar Ltd 100 ABBOTT PARK ROAD ABBOTT PARK IL 60064-6092 0 0 1 0 0001635614 Abbott Investments Luxembourg S.A R.L. 100 ABBOTT PARK ROAD ABBOTT PARK IL 60064-6092 0 0 1 0 Ordinary Shares, nominal value Euro 0.01 per share 2015-04-07 4 X 0 5250000 56.8912 D 69750000 I By Subsidiaries Call Option (Obligation to Sell) 56.8912 2015-04-07 4 X 0 1 0 D 2015-03-31 2015-04-30 Ordinary Shares 5250000 0 I By Subsidiaries (1) The Ordinary Shares of Mylan N.V. ("Mylan") described in this report are held directly by Abbott Established Products Holdings (Gibraltar) Limited and Abbott Investments Luxembourg S.a r.l (collectively, the "Subsidiaries"). Each of the Subsidiaries is an indirect, wholly-owned subsidiary of Abbott Laboratories ("Abbott"). In Abbott's capacity as the ultimate corporate parent of the Subsidiaries, Abbott may be deemed to indirectly beneficially own such Ordinary Shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Securities and Exchange Commission thereunder. (2) On March 31, 2015, the Subsidiaries and Laboratoires Fournier S.A.S., an indirect, wholly-owned subsidiary of Abbott, entered into an Underwriting Agreement (the "Underwriting Agreement") with Morgan Stanley & Co. LLC and Goldman Sachs & Co., as representatives of the several underwriters named therein, and Mylan relating to an underwritten public resale offering an aggregate of 35,000,000 Ordinary Shares. The offering transaction closed on April 6, 2015. Pursuant to the Underwriting Agreement, Abbott Investments Luxembourg S.a r.l, for no additional consideration, granted the underwriters a 30-day option to purchase up to an additional 5,250,000 Ordinary Shares for a purchase price of $56.89125 per Ordinary Share. On April 7, 2015, the representatives of the underwriters exercised the foregoing option in full. Thomas C. Freyman 2015-04-09